| Imaging Characteristics of Breast Cancer in Women Under 40 Years of Age (NCT00155038) | National Taiwan University Hospital | 1998-01-01 |
| Study of Docetaxel in Breast Cancer Patients (NCT00174707) | Sanofi | 1997-12-01 |
| Primary Progesterone Therapy for Operable Breast Cancer (NCT00123669) | Tata Memorial Hospital | 1997-10-01 |
| Boost Use in Breast Conservation Radiotherapy (NCT00138814) | St George Hospital, Australia | 1997-01-01 |
| Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers (NCT00178802) | The University of Texas Health Science Center, Houston | 1996-06-01 |
| 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer (NCT00300508) | AstraZeneca | 1996-01-01 |
| Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer (NCT00001493) | National Cancer Institute (NCI) | 1995-10-01 |
| Outcomes of Education and Counseling for BRCA1 Testing (NCT00001468) | National Human Genome Research Institute (NHGRI) | 1995-03-01 |
| Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers (NCT00579163) | Memorial Sloan Kettering Cancer Center | 1994-12-01 |
| A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients (NCT00001384) | National Cancer Institute (NCI) | 1994-05-01 |
| Positron Emission Tomography in Patients With Breast Cancer (NCT00001385) | National Cancer Institute (NCI) | 1994-05-01 |
| A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer (NCT00001378) | National Cancer Institute (NCI) | 1994-01-01 |
| A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer (NCT00001338) | National Cancer Institute (NCI) | 1993-06-01 |
| High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer (NCT00584428) | University of Oklahoma | 1992-06-01 |
| Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma (NCT00001270) | National Cancer Institute (NCI) | 1991-06-01 |
| Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer (NCT00001269) | National Cancer Institute (NCI) | 1991-05-01 |
| A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer (NCT00001193) | National Cancer Institute (NCI) | 1984-11-01 |
| An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer (NCT00051779) | Chugai Pharma USA | |
| Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies (NCT00036023) | Amgen | |
| Women's Health Initiative (WHI) (NCT00000611) | National Heart, Lung, and Blood Institute (NHLBI) | |
| Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer. (NCT00034125) | Eli Lilly and Company | |
| Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors (NCT00080041) | Pharmacyclics LLC. | |
| Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients (NCT01169792) | Yonsei University | |